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Abstract: C-reactive protein (CRP) is a commonly used serum biomarker for detecting sepsis in
neonates. After the onset of sepsis, serial measurements are necessary to monitor disease progression;
therefore, a non-invasive detection method is beneficial for neonatal well-being. While some studies
have shown a correlation between serum and salivary CRP levels in septic neonates, the causal
link behind this correlation remains unclear. To investigate this relationship, CRP was examined
in serum and saliva samples from 18 septic neonates and compared with saliva samples from
22 healthy neonates. While the measured blood and saliva concentrations of the septic neonates
varied individually, a correlation of CRP levels between serum and saliva samples was observed
over time. To clarify the presence of active transport of CRP across the blood–salivary barrier (BSB),
transport studies were performed with CRP using in vitro models of oral mucosa and submandibular
salivary gland epithelium. The results showed enhanced transport toward saliva in both models,
supporting the clinical relevance for salivary CRP as a biomarker. Furthermore, CRP regulated the
expression of the receptor for advanced glycation end products (RAGE) and the addition of soluble
RAGE during the transport studies indicated a RAGE-dependent transport process for CRP from
blood to saliva.
Keywords: neonatology; saliva diagnostics; infectious disease; immunology; neonatal sepsis; TR146;
HTB-41 (A-253)
1. Introduction
Neonatal sepsis and other neonatal infections account for 0.88% of all disability
adjusted life years worldwide, demonstrating similar percentages compared with motor
vehicle road injuries (0.98%) and asthma (0.91%) [1]. Neonatal infections are associated
with a high mortality [2], brain injury [3], and poor neurodevelopmental outcome in early
childhood [4]. Preterm infants are particularly vulnerable to infections and sepsis due
to multiple factors such as prematurity, immature host defense mechanisms, frequently
used antibiotics combined with invasive interventions, and prolonged stay in the neonatal
intensive care unit. Furthermore, clinical signs and symptoms of neonatal sepsis are
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non-specific, and the differential diagnosis is broad [5]. The adverse outcomes caused by
neonatal sepsis in combination with the non-specific symptoms call for early detection,
close monitoring, and rapid intervention. Several parameters have been tested for their
accuracy in diagnosing neonatal sepsis with clinical studies indicating the applicability
of cytokines, presepsin, or S100A2 as biomarkers for detection [6–8]. However, the most
extensively studied and frequently used laboratory test for diagnosis is based on the serum
concentration of C-reactive protein (CRP) of septic neonates [9–11]. CRP is an acute phase
reactant synthesized in the liver. It has a half-life of 21 h in neonates [12], and it takes
10–12 h for CRP to change significantly after onset of infection [9].
For the detection of neonatal sepsis CRP measurement has a sensitivity of 74–98%
and a specificity of 71–94% performed at least 12 h after the onset of symptoms [10]. Serial
measurements of CRP 24–48 h after the onset of symptoms increase the sensitivity to 82%
and the specificity to 93–96% [13]. These results make CRP the most suitable candidate
for monitoring of and routine screening for sepsis in term as well as in preterm neonates.
Serum CRP determination is limited by the need for blood sample drawing, especially in
preterm children with blood volumes of 80 mL/kg [5], where the volume of blood taken
for lab tests should be minimal. Furthermore, every blood sampling carries the risk of
infection [14] and is a painful intervention. Therefore, a non-invasive alternative to blood
collection would be a great advantage, in particular for preterm and term neonates.
Recent developments in salivary biomarker analysis favor the usage of saliva as
a non-invasively collected diagnostic fluid. As the serum/salivary ratio of biomarker
concentrations varies between biomarkers [15], sensitive detection methods, such as ELISA
or microchips, are necessary. Additionally, knowledge of the correlation between biomarker
concentrations in serum and in saliva is essential for salivary diagnostics of diseases.
While previous clinical studies with neonates indicated a positive correlation of
salivary CRP with serum CRP concentrations [16,17], a thorough understanding of the
transport mechanism from blood to saliva is still lacking. Furthermore, recent studies
were inconclusive about the usage of CRP as a salivary biomarker for detection of sepsis
in neonates [18,19]. Hence, to understand the detected correlation between saliva and
serum concentration of CRP in clinical studies, we collected serum and saliva samples
from neonates upon onset of sepsis and during sepsis as well as saliva samples from
healthy subjects for comparison. To further investigate the relevance of CRP as a salivary
biomarker, we aimed to study the transport of CRP across in vitro models of the blood–
saliva barrier (BSB), defined by the epithelial cell layers of the oral mucosa and salivary
glands [20]. The human buccal mucosa carcinoma cell line TR146 was chosen as an oral
mucosa model, which was recently thoroughly characterized by Lin et al. [21] for its
biological barrier properties including expression studies of 96 relevant barrier molecules
(cytokeratins, mucins, aquaporins, epithelial-mesenchymal transition (EMT) markers, and
tight junction proteins among others) and validation against human buccal biopsy samples.
Additionally, the integrity of the paracellular barrier was improved by optimization of
the cultivation media and conditions. As a salivary gland model, we used a barrier
model based on a single clone of the human submandibular cell line HTB-41, which was
previously described on expressions of α-amylase, tight junction proteins and markers
specific to different cell types of the salivary gland. Paracellular integrity was verified with
transepithelial electrical resistance (TEER) and permeability studies [22]. As both models
of the BSB were characterized on the expression and function of transporter proteins as
well as tissue specific markers, they were applied for assessment of biomarker transport
with ferritin recently and confirmed their suitability for transport studies in biomarker
research [22].
Since local inflammation of the oral mucosa may contribute to elevated CRP levels in
saliva [23,24], differentiating between transported CRP and locally elevated CRP presents
a challenge in the clinic. By utilizing established in vitro models of the BSB, it is possible
to study the link between salivary and serum CRP concentrations directly. Moreover, the
regulation of the transport mechanism can be examined under pre-set conditions, offering
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valuable insights in the usability of CRP as a salivary biomarker. Especially the discovery
of a transport mechanism for CRP from blood to saliva would offer an explanation for the
reported correlation between saliva and blood concentrations in clinical settings.
2. Materials and Methods
2.1. Collection of Clinical Samples
This prospective observational part was conducted at the Division of Neonatology,
Pediatric Intensive Care and Neuropediatrics at the Medical University Vienna/General
Hospital Vienna, a tertiary care academic center, consisting of two separated neonatal
intensive care units (NICU, 12 and 10 beds, level IV), two separated neonatal intermediate
care units (NIMCU, 2 × 12 beds), and 38 beds on the maternity ward with rooming-in care.
This part of the study was approved by the Ethics Committee of the Medical University
of Vienna (No. 1265/2016, 24 May 2016) and was performed in two phases. Phase one
focused on determining the salivary CRP values in healthy neonates. This was limited
to randomly selected neonates born at ≥33 weeks of gestational age and a birthweight of
≥1500 g admitted to the maternity ward without chromosomal aberrations, congenital
malformations or inborn metabolic disorders upon obtaining parental informed consent.
Saliva sampling was performed at earliest 12 h after birth and earliest 30 min after feeding
in clinically healthy neonates. Phase two consisted of evaluation of a correlation between
CRP values in saliva and blood. Neonates between 23 and 42 weeks of gestational age
admitted to the NICUs or NIMCUs with serum CRP measurements were randomly selected
and parental informed consent was obtained. Saliva sampling was performed at the earliest
timepoint within 10 h of serum CRP determination and at a minimum of 30 min after
feeding without any residues of food present. This time point was chosen based on the time
needed for significant changes in CRP values after onset of sepsis of more than 10–12 h and
to allow for ideal implementation in the care of critically ill preterm and term infants [9].
In all patients, saliva was collected using the PediaSAL device (Oasis Diagnostic,
Vancouver, WA, USA) especially developed for preterm and term infants. This device is
designed as “pacifier” with a passive collecting system based on a sponge. This allows to
obtain saliva samples of neonates enabling a non-invasive painless sampling with minimal
stress. Due to different age and bodyweight of the included neonates, the sponge was used
for collection to allow for optimum patient-oriented sampling.
Saliva sampling was most efficient when performed 60–120 min after feeding. To
maximize the amount of collected saliva, the following technique proved to be useful: The
neonate’s head was placed to the left or right, independent of supine or prone position. A
pacifier of according size was offered for 5 min prior to sampling. An increase in the saliva
production was achieved by gently stroking the lips with the pacifier or the device. After
at least five minutes with the pacifier, the sampling device was placed in the downward
cheek of the neonate, where the produced saliva collected. If the amount of saliva was not
sufficient, swapping to the pacifier for another 2 min and then back to the sampling device
helped. This was sometimes repeated several times. After sampling, the samples were
continuously cooled. Saliva was stored within 15 min at −20 ◦C and subsequently 2 h at
−80 ◦C until transport to the laboratory. Transportation was performed under continuous
cooling at −78 ◦C using dry ice.
2.2. Detection of Serum CRP in Clinical Samples
Determination of CRP concentration in serum was performed by the Department of
Laboratory Medicine of the Medical University Vienna, Vienna, Austria using the VITROS®
250/350 and VITROS® 5600 System (Ortho-Clinical Diagnostics, Raritan, NJ, USA) or using
the Cobas 6000 Chemistry Analyzer (Roche, Basel, Switzerland).
Analysis of CRP using the VITROS® Systems was performed with VITROS® CRP
slides (Ortho-Clinical Diagnostics, Raritan, NJ, USA, 23-044-667) and VITROS® Chemistry
Products Calibrator Kit 7 (Ortho-Clinical Diagnostics, Raritan, NJ, USA, 1320498). For
detection based on an HRP conjugated monoclonal anti-CRP antibody a drop of sample
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was applied on the slides and measured at wavelength 670 nm upon preparation according
to the manufacturer’s instructions. Measurement was performed at a concentration range
of 5–90 µg/mL with a limit of detection determined as 2.72 µg/mL by the manufacturer.
For detection of serum CRP concentrations with Cobas 6000 Chemistry Analyzer
the CRP-hs reagent kit (Roche, Basel, Switzerland, 4628918190) was used according to
the manufacturer’s instruction. Serum was separated from the cells within one hour
of collection and stored at −70 ◦C until measurement. Samples were thawed at room
temperature, homogenized, and centrifuged at 2000 rcf for 10 min prior to applying 100 µL
for measurement using the c501 module based on a photometric and ion-selective electrode
determination. For quality controls an internal pooled serum sample and Precipath U
Plus Control (Roche, Basel, Switzerland, 12149443160) was used. Detection limit was
determined as 0.15 µg/mL for an analytical measurement range up to 20 µg/mL according
to the manufacturer.
CRP concentration in saliva was determined using ELISAs by the Molecular Diagnostic
Unit at AIT, the Austrian Institute of Technology, Vienna, Austria, and is described in detail
in Section 2.6.
2.3. Cell Culture
The human buccal carcinoma cell line, TR146, was purchased from Sigma-Aldrich
(St. Louis, MO, USA, 10032305) and cultured in T25 flasks (Greiner, Bio-One GmbH,
Kremsmünster, Austria, CELLSTAR®, 690175) in Dulbecco’s Modified Eagle Medium
(DMEM, Sigma-Aldrich, St. Louis, MO, USA, D5796), supplemented with 10% Fetal Calf
Serum (FCS, Sigma-Aldrich, St. Louis, MO, USA, F9665) and 1% Penicillin/Streptomycin
(Pen/Strep, Merck, Darmstadt, Germany, A2213) at 37 ◦C, 5% CO2, 95% air atmosphere,
and 95% humidity. Media change was performed every 2–3 days and cells were propagated
weekly at a cell seeding concentration of 9.33 × 103/cm2. For transport studies TR146
were seeded at a cell density of 4.29 × 104/cm2 in 300 µL DMEM supplemented with 10%
FCS and 1% Pen/Strep (DMEM media) on 24-well ThinCerts (Greiner, Bio-One GmbH,
Kremsmünster, Austria, 662641) with 900 µL DMEM media provided on the basolateral
compartments in 24-well plates (Greiner, Bio-One GmbH, Kremsmünster, Austria, 662160).
To isolate protein, TR146 were seeded at a cell density of 4.29 × 104/cm2 in 2 mL DMEM
media on 6-well ThinCerts (Greiner, Bio-One GmbH, Kremsmünster, Austria, 657641)
with 3.5 mL DMEM media provided on the basolateral side. As soon as cells reached
confluency on day 5 or 8 the cultivation condition was switched from submerged to airlift
and basolateral DMEM media was changed to DMEM media supplemented with 1%
Human Keratinocytes Growth Supplements (HKGS, Thermo Fisher Scientific, Waltham,
MA, USA, S0015). Media change was performed every 2–3 days for four weeks. Cells were
used from passage 13–38 for the experiments.
The isolated clone B2 from the human submandibular cell line HTB-41 (ATCC, Virginia,
MA, USA) was cultivated in T25 flasks in McCoy’s 5A (Thermo Fisher Scientific, Waltham,
MA, USA, 16600082), supplemented with 10% FCS and 1% Pen/Strep, termed as McCoy
media, at 37 ◦C, 5% CO2, 95% air atmosphere, and 95% humidity. The isolation was
performed previously by single cell experiments using HTB-41 at passage 8 resulting in
clone B2 [22]. Cells were propagated weekly at a cell density of 8 × 103 cells/cm2 and
seeded at a density of 8 × 104/cm2 on 24-well ThinCert in 300 µL McCoy media on the
apical side, with 900 µL media provided in the basolateral side for transport studies. Clone
B2, isolated at AIT, Austrian Institute of Technology, Vienna, Austria was seeded on 6-
well ThinCerts in 2 mL McCoy media on the apical side, with 3.5 mL media provided in
the basolateral compartment for protein isolation. Media change was performed every
2–3 days until the day of the experiment on day 15 or 16. Cells seeded on 6-well ThinCerts
were lysed for protein isolation on day 16. B2 clone was isolated at passage 8 from the
parental cell line and subsequently used for experiments at passage 32-48 upon the passage
of isolation.
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2.4. Transport Studies with CRP
On the day of experiment, cell layers of TR146 were washed twice on the apical
(300 µL) and basolateral (900 µL) side with Hank’s Balanced Salt Solution (HBSS, Sigma-
Aldrich, St. Louis, MO, USA, H6648), while cell layers of the B2 clone were washed twice
with basal McCoy media (McCoy’s 5A without supplements). TEER was measured in
both models (detailed description in the Supplementary Materials section) to confirm the
integrity of the paracellular barrier of the models. Human CRP (Sigma-Aldrich, St. Louis,
MO, USA, C4063, 118 kDa, 1 mg/mL in 20 mM TRIS containing 280 mM NaCl) was diluted
1:100 to 10 µg/mL in HBSS or basal McCoy media containing 1% 20 mM TRIS (Roth, Basel,
Switzerland, 5429.3, 20 mM) and 280 mM NaCl (Sigma-Aldrich, St. Louis, MO, USA, S7653).
HBSS or basal McCoy was replaced with 10 µg/mL CRP on the apical side for transport
studies from the apical to the basolateral compartment (A/B) or on the basolateral side for
transport studies from the basolateral to apical compartment (B/A).
For transport studies of CRP with the soluble Receptor for Advanced Glycation
End products (sRAGE, R&D Systems, Minneapolis, MN, USA, 1145-RG), sRAGE was
dissolved in PBS (Thermo Fisher Scientific, Waltham, MA, USA, 14190-094) to 100 µg/mL
and subsequently diluted 1:20 in HBSS or basal McCoy containing 1% TRIS, 5% PBS, and
10 µg/mL CRP shortly before the experiment. Media composition was adapted accordingly
for all samples and controls during transport studies. Samples on the apical and basolateral
side were collected after 24 h and stored at 4 ◦C until quantification with ELISA. Cell
layers of two 24-well ThinCert were lysed with 350 µL RA1 buffer (Machery-Nagel, Düren,
Germany, 740961) supplemented with 1% ß—Mercaptoethanol and pooled as one biological
sample for RNA isolation.
2.5. ELISA for Cell Culture Samples
Transparent high-binding 96-well plates (Corning, Somerville, MA, USA, 3366) were
coated with 100 µL 2 µg/mL Human CRP antibody (R&D Systems, Minneapolis, MN, USA,
842676) in PBS [137 mM NaCl (Sigma-Aldrich, St. Louis, MO, USA, S7653), 2.7 mM KCl
(Merck, Darmstadt, Germany, 104936), 8.1 mM Na2HPO4 (Merck, Darmstadt, Germany,
106586), 1.5 mM KH2PO4 (Merck, Darmstadt, Germany, 104873), pH 7.3] overnight at
4 ◦C under orbital shaking conditions sealed with aluminum foil. Prior to usage on the
next day, each well was washed three times with 300 µL PBS containing 0.05% Tween
20 (Sigma-Aldrich, St. Louis, MO, USA, P7949; 0.05% Tween 20/PBS) and blocked with
300 µL/well carbonate-bicarbonate buffer (Sigma-Aldrich, St. Louis, MO, USA, C3041)
containing 1% BSA (Roth, 0163.2) for 1.5 h at room temperature under orbital shaking
conditions sealed with aluminum foil. Consecutively, wells were washed three times with
300 µL/well 0.05% Tween 20/PBS prior to applying the samples.
Samples from the transport studies of the receiving compartment were diluted 1:50;
applied CRP or CRP/sRAGE stock solutions 1:2000 in HBSS or basal McCoy containing 1%
TRIS for transport studies with CRP and in HBSS or McCoy containing 1% TRIS and 5%
PBS for transport studies with CRP and sRAGE. A calibration curve (0, 0.5, 1, 1.25, 2.5, 10,
20 ng/mL) with Human CRP Standard Antigen (R&D Systems, Minneapolis, MN, USA,
842678) was prepared in the respective HBSS or basal McCoy composition used for the
dilution of the samples. The diluted samples and the samples for the calibration curve were
additionally diluted 1:2 in PBS containing 1% BSA and 20 mM EDTA (Merck, Darmstadt,
Germany, 324503) in a non-binding 96-well plate (Corning, Somerville, MA, USA, 3461) and
applied as duplicates with 100 µL/well on the previously coated high binding 96-well plate.
The plate was incubated for 1 hour at room temperature sealed with aluminium foil under
orbital shaking conditions. Afterwards, wells were washed three times with 300 µL/well
0.05% Tween 20/PBS following an incubation step with 100 µL/well of 30 ng/mL detection
antibody (R&D Systems, Minneapolis, MN, USA, 842677) diluted in PBS containing 1%
BSA (1% BSA/PBS) for 1 h at room temperature sealed with aluminum foil under shaking
conditions. After further washing steps, applying 300 µL/well 0.05% Tween 20/PBS
for three times, 100 µL/well streptavidin-HRP (R&D Systems, Minneapolis, MN, USA,
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890803), diluted 1:200 in 1% BSA/PBS, was added and incubated for 20 min under shaking
conditions sealed with aluminum foil at room temperature. After washing three times with
0.05% Tween 20/PBS, 100 µL/well 1-StepTM Ultra TMB-ELISA substrate solution (Thermo
Fisher Scientific, Waltham, MA, USA, 34028) was added and the plate was incubated in the
dark for 20 min at room temperature.
To stop the reaction 50 µL/well of 1 M HCl (Roth, Karlsruhe, Germany, 6792.1)
was added and absorbance was measured at 450 nm with the EnSpire® 2300 Multimode
Plate Reader (PerkinElmer, Waltham, MA, US). Permeability coefficient was calculated as
apparent permeability values (Papp) in [cm/s] using the formula shown below (Equation
(1)) with crec as a measured concentration in the receiving side in µg/mL, Vrec the volume
on the receiving compartment in mL, A as the area in cm2, c0 as the stock solution in
µg/mL, and t as duration in seconds.
Papp =
crec × Vrec
dt × A × c0
(1)
2.6. ELISA for Saliva Samples
Due to the small saliva volumes of neonates in the range of 30–100 µL, the ELISA
method from Section 2.5 had to be adapted to handle 1/5 of the volume. Half-area plates
were used (Corning, Somerville, MA, USA, 3690) and the volumes for coating, detection
antibody incubation, streptavidin-HRP incubation, and substrate incubation were reduced
from 100 µL to 20 µL. Washing and blocking volumes were adjusted from 300 µL to
150 µL. The detection antibody was applied at 100 ng/mL instead of 30 ng/mL. To stop
the reaction, 10 µL HCl were used instead of 50 µL. Saliva and standards were diluted 1:2
in 1% BSA/PBS and applied as duplicates using 20 µL/well. All incubation and washing
steps were performed under the conditions as described above. Samples were measured
with the EnSpire® 2300 Multimode Plate Reader (PerkinElmer, Waltham, MA, USA) at
450 nm as described above.
2.7. Quantitative Real-Time PCR
For RNA isolation of cell lysates, the NucleoSpin RNA Kit (Machery Nagel, Düren,
Germany, 740961) was used according to the manufacturer’s instruction and eluted with
40 µL nuclease-free water (Invitrogen, Carlsbad, CA, USA, AM9937). For cDNA synthesis
with the Multiscribe Reverse Transcriptase Kit (Thermo Fisher Scientific, Waltham, MA,
USA, 4311235) 200 ng RNA were applied for clone B2 while 1000 ng RNA were applied for
TR146. Quantitative real-time PCR was performed as triplicates in white 96-well plates
(4titue, Dorking, UK, 4ti-0951) with 20 µL reaction volume consisting of 4 µL 1:10 in
nuclease-free water diluted cDNA, 2.8 µL 3 µM primer pairs, 3.2 µL nuclease-free water,
and 10 µL PowerUpTM Sybr Green Kit (Thermo Fisher Scientific, Waltham, MA, USA,
A25742). Primer sequences are shown in Table 1 and were verified with PrimerBLAST [25].
Prior to usage in qPCR, amplicon sizes were evaluated using 2% agarose gels, described
in detail in Lin et al. [21], followed by a two-fold dilution series for calculation of primer
efficiency performed via qPCR similarly as described by Pfaffl [26]. Primer efficiency was
required to be 80–120% to pass for further usage.
Table 1. Applied primer sequences for 18SrRNA, Peptidylpropyl Isomerase A (PPIA) and Receptor
for Advanced Glycation End Products (RAGE).




The program for qPCR was set for 20 sec at 95 ◦C for activation, running 40 cycles for
3 s at 95 ◦C, and 30 s at 60 ◦C, following a melting stage of 15 s at 95 ◦C, 1 min at 60 ◦C, and
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15 s at 95 ◦C using the LightCycler 480 II (Roche, Basel, Switzerland). Data was acquired
with the LightCycler480 V1.5 software (Roche, Basel, Switzerland).
For data analysis, ∆Ct values were calculated by subtracting Ct vales of the endoge-
nous control from the respective Ct values of the analyzed target. ∆Ct values of treated
samples were normalized to untreated samples upon exponentiating by 2 as shown with





On the day of the experiments, cell layers seeded on 6-well ThinCert were washed
twice with HBSS (TR146) or basal McCoy (clone B2) on the apical and basolateral side
prior to the incubation with HBSS or basal McCoy containing 10 µg/mL CRP or 1% 20 mM
TRIS and 280 mM NaCl on the apical and basolateral side for 24 h. Afterwards, cell layers
were washed twice with pre-cooled PBS and incubated for 5 min in PBS after the last
washing step on ice. For lysis, 50 µL RIPA buffer (50 mM TRIS pH 8.0; 150 mM NaCl, 0.1%
SDS, 0.5% sodium-deoxycholate, 1% NP40), supplemented with complete ULTRA protease
inhibitor cocktail and PhosphoSTOP minitablet (Roche, Basel, Switzerland, 05892970001
and 04906837001) was added for 30 min on ice. Protein lysates were collected with a cell
scraper, and protein concentration was determined with Pierce BCA assay kit (Thermo
Fisher, Scientific, Waltham, MA, USA, 23227) according to the manufacturer’s instructions.
Western blotting was performed as described in detail previously [27,28]. In short,
20 µg protein was loaded from each sample, and the primary antibody for RAGE (A-9,
Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-365154, mouse) was applied 1:200–
1:300 in 5% nonfat dried milk (ITW reagents, Chicago IL, USA, A0830,0500). Subsequently,
the HRP-labeled anti-mouse antibody was applied 1:5000 diluted in 5% nonfat dried milk
(Cell Signaling Technology, Danvers, MA, USA, 7076S). For visualization of endogenous
control ß-actin, HRP-labeled ß-actin antibody (Sigma-Aldrich, St. Louis, MO, USA, A3854,
7076S) was applied 1:20,000 in 5% nonfat dried milk. Signals were captured with ChemiDoc
Imaging system (Bio-Rad, Berkeley, CA, USA), densitometric analysis was performed with
ImageLab Software Version 5.2 (Bio-Rad, Berkeley, CA, USA). For analysis of RAGE both
detected bands were included in the analysis according to literature describing isoforms of
RAGE [29].
2.9. Statistical Data Analysis
Results are shown as mean ± SEM unless otherwise indicated. Graphs and statistical
analysis were illustrated or performed with SigmaPlot 14.0 (Systat, Jose, CA, USA). Statistical
analysis was performed as Mann-Whitney Rank Sum test, Student’s t-test, or two-way ANOVA
followed by post-hoc Holm-Sidak test with α = 0.05, p < 0.05 *, p < 0.01 **, p < 0.001 ***.
3. Results
3.1. Analysis of Clinical Samples Propose Individual Correlations between Serum and Salivary
CRP Concentrations
In this study, 18 neonates (six females) undergoing sepsis were investigated on their
CRP levels in serum and saliva (characteristics of neonates are shown in Table 2).
Nine neonates had one, five neonates had two, two neonates had three, and two
neonates had four CRP measurements analyzed over a maximum period of nine days.
Sepsis at the time point of sampling was indicated by a threshold of >15 µg/mL CRP
in serum.
Estimated values of CRP in serum and saliva at time point of sepsis varied with
76.40 ± 79.79 µg/mL in serum and 93.70 ± 161.01 ng/mL in saliva (mean ± SD, n = 22,
median: 4.2 µg/mL and 18.55 ng/mL) resulting in a median ratio between salivary and
serum concentration of 1600 (5300 ± 10,100, mean ± SD). However, comparing all measured
saliva to serum concentrations (n = 33) led to a highly significant correlation between
clinical saliva and serum values (Pearson correlation r = 0.72, p < 0.001, y = −6.39x + 1.36,
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R2 = 0.52) as shown in Figure 1A. Specifically, an individual correlation of saliva and serum
concentrations over time was observed for septic neonates. Exemplary time courses of
three neonates over 4 or 9 days are illustrated in Figure 1B.
Table 2. Characteristics of neonates at test with corresponding serum C-reactive protein (CRP)
concentrations shown as mean ± SD (minimum (min.)–maximum (max.)) or numbers (n) and
percentage (%).
Characteristics (n = 33 in 18 Patients) Mean ± SD (Min.–Max.)/n (%)
Gestational age at birth (w) 33.1 ± 5.44 (25.4–40.6)
Corrected age at test (w) 38.4 ± 7.6 (28.4–55.4)
Day of life at test (d) 33.3 ± 44.7 (1–143)
Birth weight (g) 2170 ± 1130 (580–4400)
Body weight at test (g) 2870 ± 1330 (790–5040)
Female patients (n) 6 (33%)
CRP > 15 µg/mL at test (n) 22 (66%)
w—week; d—day; g—gram; n—number.
Figure 1. CRP concentration in serum [µg/mL] and corresponding concentration in saliva [ng/mL] of 18 neonates
(gestational age at birth 33.10 ± 5.44 weeks, six females) over 1–4 time points (n = 33). Serum concentration of CRP was
measured with 53.12 ± 72.82 µg/mL (mean ± SD, maximum at 320 µg/mL and minimum at 0.3 µg/mL). Salivary CRP
was measured with 65.73 ± 137.70 ng/mL (mean ± SD, maximum at 489 ng/mL and minimum at 0.12 ng/mL). Pearson’s
correlation was calculated as r = 0.72 (p < 0.001) with y = −6.388x + 1.358, R2 = 0.52. Concentrations indicating severe sepsis
(>80 µg/mL CRP in serum) were circled in red (A). Time course of measured salivary [ng/mL] and serum [µg/mL] CRP
concentration over 4–9 days from three selected neonates (NN1–NN3) with gestational age of 29 + 1, 35 + 0, and 30 + 1
(week + day) (B).
For comparison of salivary CRP concentrations from septic neonates to baseline saliva
levels, samples from 22 healthy neonates (eleven females, Table 3) were measured resulting
in significantly lower 14.15 ± 16.63 ng/mL CRP levels in saliva (mean ± SD, median:
6.30 ng/mL, n = 22, p < 0.05).
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Table 3. Characteristics of healthy neonates without corresponding serum CRP concentrations shown
as mean ± SD (minimum (min.)–maximum (max.)) or numbers (n) and percentage (%).
Characteristics (n = 22) Mean ± SD (Min.–Max.)/n (%)
Gestational age at birth (w) 38.6 ± 1.6 (35.7–40.9)
Corrected age at test (w) 39.0 ± 1.6 (36.6–41.6)
Day of life at test (d) 2.8 ± 1.5 (1–6)
Birth weight (g) 3190 ± 610 (2090–4090)
Female (n) 11 (50%)
CRP > 15 µg/mL at test (n) 0 (0%)
w—week; d—day; g—gram; n—number.
3.2. Transport of CRP Across BSB In Vitro Models Indicate the Presence of Active Carrier Systems
Clinical data displayed similar progressions of salivary and serum CRP levels for
individual neonates over time and indicated a correlation between saliva and serum
values. Therefore, we aimed at investigating the transport of CRP between blood and
saliva. For this purpose, as a first step 10 µg/mL CRP was added to the oral mucosa
epithelium in vitro model on both the apical and basolateral side during preliminary
equilibrium studies (Supplementary Materials Figure S1). The data showed a decrease
of CRP concentration over time on the basolateral side, indicating a possible transport
mechanism in the oral mucosa model.
To study a possibly directed transport in more detail, 10 µg/mL CRP was applied
on the basolateral (B/A) or apical side (A/B) for 24 h in the oral mucosa and the sali-
vary gland epithelium model. Significant barrier properties of both in vitro models were
confirmed by TEER values of 238.88 ± 54.92 Ω × cm2 for the oral mucosa model and
482.70 ± 25.25 Ω × cm2 for the salivary gland epithelium model, respectively (raw data:
Oral mucosa model: Cells 1015.63 ± 163.45 Ω, blanks 304.67 ± 8.41 Ω; Salivary gland
model: Cells 1738.92 ± 74.60 Ω, blanks 302. 33 ± 2.59 Ω).
Apparent permeability Papp values for the oral mucosa model resulted in a 2.58 ± 0.39-fold
higher permeability of CRP from B/A upon normalization to Papp values from A/B
(1.00 ± 0.05, p < 0.01; A/B Papp: 0.11 ± 0.028 × 10
−6 cm/s, B/A Papp: 0.21 ± 0.058 ×
10−6 cm/s), shown in Figure 2. On the other hand, applying 10 µg/mL CRP in the salivary
gland model led to a significantly higher permeability from B/A with 2.23 ± 0.26-fold
upon normalization to Papp values from A/B (1.00 ± 0.06, p < 0.001; A/B Papp: 0.013
± 0.001 × 10−6 cm/s, B/A Papp: 0.029 ± 0.003 × 10
−6 cm/s). In summary, these data
clearly indicated the presence of a directed transport mechanism for CRP across the in vitro
models of the BSB.
3.3. CRP Treatment Modifies the Expression of Receptor for Advanced Glycation Endproducts
(RAGE) In Vitro
Previous literature indicated the involvement of RAGE in inflammatory response
upon treating endothelial progenitor cells with CRP [30], followed by a subsequent study
describing the correlating levels of RAGE and CRP in serum [31].
To examine a possible involvement and regulation of RAGE by CRP, cell samples from
the transport studies were analyzed and compared to untreated cell samples at the mRNA
and protein level. As a result, the mRNA regulation showed a similar tendency as the Papp
values described above.
In the oral mucosa model the addition of CRP resulted in no statistically significant
regulation of the mRNA expression of RAGE, only a tendency for increased RAGE ex-
pression was observed (1.58 ± 0.56-fold (B/A), 1.41 ± 0.22-fold (A/B), p = 0.56). On the
contrary, applying CRP in the salivary gland model on the basolateral (B/A) side led to a
significant downregulation to 0.85 ± 0.06-fold for RAGE compared to an upregulation of
2.14 ± 0.65-fold upon applying CRP on the apical (A/B) side (Figure 3A,B).
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Figure 2. Apparent permeability (Papp) of 10 µg/mL CRP applied on the apical (A/B) or basolateral
(B/A) side for 24 h in the oral mucosa model, based on TR146 cells, and salivary gland model, based
on clone B2 of HTB-41 cells. Results calculated as x-fold referred to Papp A/B, shown as mean ± SEM
after referring to Papp values for A/B of each individual experiment of in total three independent
experiments (N = 11–13). Statistical analysis was performed as Student’s t-test with α = 0.05, p < 0.01
**, p < 0.001 ***.
At the protein level (Figure 3C,D), the exposure to CRP on both the apical and basolat-
eral side led to a slight upregulation of RAGE in the oral mucosa model (1.07 ± 0.07, mean
± SEM) compared to control samples (1.00 ± 0.03, mean ± SEM). In the salivary gland
model exposure to CRP on the apical and basolateral side led to a significant upregulation
of 1.32 ± 0.11-fold (mean ± SD, p < 0.05) compared to control samples with 1.00 ± 0.04
(mean ± SEM) (Figure 3E,F).
3.4. Soluble RAGE Alters the Transport of CRP In Vitro
To investigate the role of RAGE on the transport of CRP, transport studies with
5 µg/mL soluble RAGE (sRAGE) and 10 µg/mL CRP on the basolateral or apical side were
performed and compared to the permeability of CRP alone in both models for each exper-
iment. In the oral mucosa model, transport of CRP from B/A showed a 2.22 ± 0.21-fold
higher permeability compared to A/B (1 ± 0.29, p < 0.01, Papp: A/B 0.12 ± 0.017 ×
10−6 cm/s, B/A 0.22 ± 0.030 × 10−6 cm/s), similar to above. Upon normalization to Papp
values from A/B, the addition of sRAGE led to a similar apparent permeability value of
CRP from A/B (0.95 ± 0.08, 0.11 ± 0.0098 × 10−6 cm/s), but decreased the transport of
CRP from B/A significantly to 1.50 ± 0.08-fold (0.19 ± 0.020 × 10−6 cm/s, p < 0.001) in
comparison to transport of CRP from B/A without addition of sRAGE.
In the salivary gland model, addition of sRAGE led to a non-significant, slightly
increased permeability of CRP from A/B (1.26 ± 0.11-fold, 0.026 ± 0.002 × 10−6 cm/s)
compared to CRP alone from A/B (1.00 ± 0.034-fold, 0.022 ± 0.009 × 10−6 cm/s, p = 0.44).
In case of the transport B/A, addition of sRAGE resulted in a significantly upregulated per-
meability of CRP (2.63 ± 0.22-fold normalized to Papp A/B CRP (0.06 ± 0.003 × 10
−6 cm/s))
compared to CRP alone (1.79 ± 0.017-fold, 0.03 ± 0.003 × 10−6 cm/s) (Figure 4).
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Figure 3. Messenger RNA expression of RAGE of the oral mucosa model (TR146, A) and salivary
gland model (B2 clone, B) after applying CRP on the apical (api) or basolateral (baso) side for 24 h,
Ct values were referred to the endogenous control (18sRNA for oral mucosa or PPIA for salivary
gland) and normalized to untreated control samples. Results shown as mean ± SEM of two–three
independent experiments (N = 4–7). Statistical analysis was performed as one-way ANOVA on ranks
with α = 0.05, * p < 0.05. Representative western blots of RAGE and ß-actin of the oral mucosa model
(TR146, C) and the salivary gland model (B2 clone, D) after treatment with 10 µg/mL CRP for 24 h
on the apical and basolateral side, compared to control samples. Densitometric values of western
blots from two—three independent experiments (N= 3) for the oral mucosa model (TR146, E) and
salivary gland model (B2 clone, F) shown as mean ± SEM. Statistical analysis was performed as
Student’s t-test, with α = 0.05, p < 0.05 *.
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Figure 4. Apparent permeability (Papp) values of the oral mucosa and salivary gland model upon
applying 10 µg/mL CRP or 10 µg/mL CRP + 5 µg/mL sRAGE on the apical (A/B) or basolateral
(B/A) side for 24 h. Results shown as mean ± SEM of two–six independent experiments (N = 7–24)
upon normalization to Papp CRP values from A/B. Outliers were excluded applying Grubb’s test.
Statistical analysis was performed as two-way ANOVA, post-hoc Holm-Sidak test with α = 0.05,
p < 0.01 **, p < 0.001 ***.
4. Discussion
CRP is widely used as an inflammatory biomarker in serum and associated with
cardiovascular diseases at levels >10 µg/mL [32]. Recently, an elevated CRP baseline was
also linked to a faster progression of Amyotrophic Lateral Sclerosis (ALS) compared to
patients with lower CRP baselines [33]. Additionally, higher CRP levels were measured in
patients suffering from schizophrenia, possibly linked to inflammation in the pathogenesis
of schizophrenia [34]. Furthermore, elevated CRP levels were also determined in patients
with SARS-Cov-2 [35], demonstrating its clinical relevance for a broad range of diseases.
First clinical studies using CRP as biomarker to detect bacterial infections were per-
formed in the late 1980s, and CRP was used in the 1990s for detection of septic neonates
showing promising clinical usage of CRP for diagnosis of neonatal sepsis [36–39]. The most
recent study correlating neonatal sepsis with elevated levels of CRP and IL-6 was published
by Cortes et al. and demonstrated that CRP could be a useful biomarker in combination
with other inflammatory biomarkers, especially for late-onset neonatal sepsis [40]. Recently,
14 clinical studies were summarized by Pay and Shaw [41] ) showing a correlation of
salivary CRP and serum CRP levels with R2 of 0.53 ± 0.23, comparable to the result of
our study with a R2 value of 0.52 (Figure 1A). Patients with samples drawn at several
time points (Figure 1B) in this study showed a median ratio between salivary and serum
concentration of 1600 (5300 ± 10,100, mean ± SD) similar to the ratio found in a clinical
study with 61 healthy volunteers by Ouellet-Morin et al. [23] reporting a ratio of 1633. This
ratio was below the assumed factor of 10,000 described by Pay and Shaw [41].
However, Pay and Shaw [41] also stressed the necessity to understand the corre-
lation of salivary and serum concentrations as local oral inflammation cannot be ex-
cluded in clinical set-ups. Even though clinical studies linked salivary CRP positively
as a marker for metabolic syndrome [42], detection of obesity in children [43], or pneumo-
nia in neonates [17], a study published in 2019 with 37 healthy young males showed no
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clear correlation between salivary and serum concentrations of CRP [44]. Additionally,
even though CRP is commonly used as a marker for neonatal sepsis, recent clinical stud-
ies claimed the need of other salivary markers for diagnosis due to unreliable screening
validity of salivary CRP [18,19,40].
Because of this contradicting data basis for CRP as a salivary biomarker, we measured
the CRP concentrations in saliva and serum samples of septic neonates to clarify the clinical
relevance of CRP in this setting. As our clinical study showed a correlation between saliva
and serum concentrations, especially for measurements taken over several timepoints, we
decided to study the transport mechanism of CRP using in vitro models of the BSB.
For this purpose, we applied 10 µg/mL CRP in our oral mucosa and salivary gland
model, as CRP concentrations of >8.7 µg/mL are associated with infections (together
with high temperature), and clinically relevant concentrations of 10–20 µg/mL have also
been used for studies with in vitro models of the blood–brain barrier previously [45,46].
While concentrations of 120 µg/mL CRP are measured in clinical settings in neonates [16],
we focused on the cut-off concentration of CRP associated with infections to evaluate
the diagnostic potential of CRP upon on-set of sepsis. Preliminary equilibrium studies
with CRP in our oral mucosa model showed a reduced concentration in the basolateral
compartment over 24 h, which was the first indication for a possible transport mechanism
(Figure S1). Applying CRP in our oral mucosa and salivary gland epithelial models either
on the apical (A/B) or basolateral side (B/A) (Figure 2) showed an elevated transport in the
direction of saliva (B/A) in both models. In total, a transported average of 54 ng or 6.77 ng of
CRP (molecular weight 118 kDa) was measured on the basolateral side after A/B transport
in the oral mucosa and salivary gland model, respectively, while significantly higher
amounts of CRP were detected in the apical compartment (oral mucosa: 112 ng; salivary
gland model: 14 ng CRP) after B/A transport. These differences already confirmed the
presence of directed transport processes for CRP in both models. To exclude that directed
B/A transport is a compound-independent model intrinsic property, permeability studies
with paracellular marker FD4 (molecular weight of 4 kDa) were accomplished (Figure
S2). Data revealed no significant difference between FD4 transport from B/A and A/B
in both models supporting that distinct transport mechanism for CRP are present in both
models. Moreover, average Papp values of FD4 (oral mucosa model: 0.56-0.59 × 10
−6 cm/s;
salivary gland model: 0.29–0.33 × 10−6 cm/s) were concordant to the corresponding TEER
values of the models and confirmed the stronger paracellular tightness of the salivary
gland model.
Since literature data indicated a linkage between RAGE and CRP [31,47], we tested
the expression of RAGE at the mRNA level of both models after CRP treatment resulting
in effects on the expression pattern of RAGE similar to the permeability values of the
transport studies with CRP (Figure 3A,B).
This revealed that mRNA levels of RAGE are subject to regulation by CRP in an
exposure side dependent manner. With regulation of RAGE after CRP treatment on the
protein level, we decided to examine the possible involvement of RAGE in the transport of
CRP. For this, we added soluble RAGE (sRAGE) to CRP for further transport studies.
In the oral mucosa model, this resulted in a significantly decreased permeability of
CRP from B/A, while addition of sRAGE in the salivary gland model led to a significantly
enhanced transport from B/A (Figure 4). In detail upon addition of sRAGE, a total
transported average of 45.7 ng or 6.8 ng CRP was detected on the basolateral side after A/B
transport in the oral mucosa and salivary gland model, respectively, while 74.6 ng (oral
mucosa model) or 19.4 ng (salivary gland model) CRP was found on the apical side after
B/A transport. Hence, addition of sRAGE elucidated RAGE-dependent CRP transport
mechanisms in both models. Interestingly, mRNA expression of RAGE was not affected by
addition of sRAGE to CRP in comparison to CRP alone in both models (data not shown)
indicating that effects of sRAGE seemed to be restricted to the functional level of RAGE.
In this context, it was shown that RAGE can mediate uptake as well as efflux transport
processes [48,49]. In relation to our results, it could be speculated that RAGE mediates
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the uptake of CRP into saliva across the oral mucosa epithelium, whereas it is involved
in efflux mechanisms to restrict exorbitant accumulation of CRP in saliva via the salivary
gland epithelium.
Corresponding to the detected correlation of CRP in saliva and serum samples of
neonates undergoing sepsis, both in vitro models of the BSB showed an elevated transport
of CRP in the direction of saliva. While the favorable transport to saliva was shown in
this study and the influence of RAGE on CRP transport was described, further studies
regarding the underlying mechanisms would improve our current knowledge about the
causal link between serum and salivary CRP and strengthen the relevance of CRP as
a salivary biomarker in general. Future studies could aim at the identification of the
responsible transporters, for example, by immunoprecipitation followed by mass analysis
to screen for proteins binding to CRP in the cellular membrane fraction.
5. Conclusions
In this study on measurement of serum and salivary CRP levels, clinical data suggest
that studying individual ratios and progression is more useful than relying on the mea-
surement of a single time-point. Additionally, in vitro data using established models of the
BSB show that CRP is preferentially transported to the direction of saliva, enhancing its
feasibility as a salivary marker. Moreover, RAGE seems to be involved in the transport of
CRP across the BSB. Future studies could focus on elucidation of the details of the transport
mechanism of CRP across the BSB.
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-4
923/13/2/256/s1, Figure S1: Measured CRP concentrations in equilibrium studies at 2, 6, and 24 h
using 10 µg/mL CRP in HBSS with the oral mucosa model based on TR146 cells. Values were
compared to concentrations measured after 2 h and shown as % as mean ± SD with N = 7–8 of three
independent experiments. Statistical analysis was performed with one-way ANOVA with post-hoc
Holm-Sidak test, α = 0.05, p < 0.001 ***; Figure S2: Apparent permeability (Papp) for FD4 after 24 h
from the apical to the basolateral side (A/B) and from the basolateral to the apical (B/A) side. Values
shown as mean ± SEM (N = 4). Statistical analysis was performed as Student’s t-test with, α = 0.05
with p = 0.87 between A/B and B/A for the oral mucosa model and p = 0.41 between A/B and B/A
for the salivary gland model.
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